Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDDate | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/14/2024 | Q3 2024 | -$0.06 | $0 | |||
08/19/2024 | Q2 2024 | -$0.02 | $0 | |||
05/15/2024 | Q1 2024 | -$0.01 | $0 | |||
04/17/2024 | Q4 2023 | -$0.01 | $0 | |||
11/07/2023 | Q3 2023 | $0.01 | $0 | |||
08/14/2023 | Q2 2023 | $0.03 | $0 | |||
05/22/2023 | Q1 2023 | $0.02 | $0 | |||
03/31/2023 | Q4 2022 | -$0.00 | $0 | |||
09/29/2022 | Q3 2022 | -$0.00 | $0 | |||
06/29/2022 | Q2 2022 | -$0.00 | $0 | |||
03/30/2022 | Q1 2022 | $0.00 | $0 | |||
12/30/2021 | Q4 2021 | $0.00 | $0 | |||
09/29/2021 | Q3 2021 | $0.00 | $0 | |||
06/29/2021 | Q2 2021 | -$0.00 | $0 | |||
03/30/2021 | Q1 2021 | $0.00 | $0 |
The conference call for Bellevue Life Sciences Acquisition Corp.'s latest earnings report can be listened to online.
The conference call transcript for Bellevue Life Sciences Acquisition Corp.'s latest earnings report can be read online.
Bellevue Life Sciences Acquisition Corp. (:BLAC) has a recorded net income of $0. Bellevue Life Sciences Acquisition Corp. has generated $0.0718 earnings per share over the last four quarters.
Bellevue Life Sciences Acquisition Corp. (:BLAC) has a price-to-earnings ratio of -96.59 and price/earnings-to-growth ratio is 0.55.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED